Sophie Ameloot, Co-founder and Sales Lead at MedInsights and Soham Saha, Co-Founder and Scientific Lead at MedInsights, MedInsights
Sophie Ameloot, Co-founder and Sales Lead at MedInsights and Soham Saha, Co-Founder and Scientific Lead at MedInsightsOver the years, due to the increasing interest in understanding biological systems and the advancement of high-throughput analytical technologies, significant strides have been made in omics sciences. From the days of first-generation DNA sequencing machines to the latest Next Generation Sequencing (NGS) systems, these advances have provided valuable insights to identify pathophysiology, understand drug interactions and develop personalised medicines.

A typical challenge that translational researchers in clinical settings, pharmaceutical R&D, and academic centres face is integrating and analysing large datasets with high-dimensional omics data, resulting from examining individual subject samples. However, such instruments generate high amounts of data that need to be handled and processed to extract the relevant information. Researchers need a combined end-to-end solution that helps to find quickly, enter, integrate, analyse, extract, and share patient- and drug-related data in the context of translational R&D projects. That said, addressing the needs of the customer requires a customised pipeline rather than a standardised pipeline. This places the additional responsibilities of planning, development, testing, and maintenance on research teams which may not be feasible for all organisations.

"We take great pride in learning from each project we undertake and in our consistent efforts to co-create with a customer in designing tailor-made, flexible and agile solutions"

In this regard, MedInsights has been transforming clinical and pre-clinical research data into actionable insights by enabling them to identify salient features in the data using data analytics tools for translational research. The company’s team has in-depth experience designing research approaches and insights from real-world data to understand scientific, biological mechanisms and develop new methodologies to overcome challenges in the biomedical insights space. Recently, MedInsights have been attempting to design and understand viral pathogenesis in light of COVID-19 to formulate a putative vaccine strategy. Furthermore, having published papers in peer-reviewed journals, its experts have extensive expertise in neuroscience systems, molecular biology, protein modelling, and simulations. “Our end-to-end analytics services aim to provide an edge to customers and enable them to understand their performance, while at the same time maintaining the rigorous standards of scientific protocols, “explains Soham Saha, Co- Founder and Scientific Lead at MedInsights.

Leveraging Best- Practices and Developing Enrich Solutions through Collaboration

Established in 2020, MedInsights initially began by offering omics analysis tools to its clients.

MedInsights: Transforming Pre-clinical and Research Data into Actionable Insights

We try to focus on existing knowledge, aim to understand the following paradigm shifts, and seek novel technologies to perform in-house research parallel to our consulting services

However, when they secured their first significant contract in the pharma industry, the company started developing and extending the scope of its solutions to provide end-to-end analytics for biomedical insights. Furthermore, MedInsights has also begun conceptualising and setting up databases of rare diseases, offering its customers rich insights into translational research. “We take great pride in learning from each project we undertake and in our consistent efforts to co-create with a customer in designing tailor-made, flexible and agile solutions,” states Sophie Ameloot, Co-founder and Sales Lead at MedInsights.

Although experts at MedInsights have an established standard methodology to analyse, understand and provide actionable insights to proteomics, genomics, and transcriptomics data, its offerings are based on a client’s long-term and short-term needs. The company constantly adapts and customises solutions to meet a client’s core requirements rather than implement pre-made and one-size-fits-all solutions. An exciting aspect of MedInsights is its unique collaborative approach to developing its client’s solution. The company’s team of experienced scientists who are exceptionally skilled at designing diagnostic methods from real-world data and understanding mechanisms in genomics and proteomics work with collaborators with diverse expertise in the fields of neurosciences, bioinformatics, and more. This enables MedInsights to leverage the best practices from each domain and incorporate them into its methodologies to create an enriched solution for its clients. Another essential feature of the company is its genuine focus on conducting all research and studies in-house and ensuring that they are updated with the latest technological trends and discoveries. “We not only try to lay our focus on existing knowledge, but also aim to understand the next paradigm shifts and seek novel technologies to perform in-house research parallel to our consulting services,” adds Sophie.

Manish Sarkar, a senior clinical scientist involved in performing in-house research projects at MedInsights, cites a case study to illustrate the company’s efficacy further. In light of the pandemic, he has been involved in deciphering the mechanism of COVID-19 using proteomics, structural modelling, and molecular dynamics. Following that, MedInsights has published three articles in peer-reviewed journals and provided analysis of the SARS-CoV-2 proteome, which impacts the complex interaction network of viral partners. These mechanistic understandings were crucial cogs in the development of drugs and vaccines. This way, MedInsights aims to fill the gap between academic research and industrial development by shunting that domain.
It facilitates studies that can be easily scaled to generate multiple drugs using the knowledge of host-pathogen interactions.

A Global Multidisciplinary Team at the Core of the Company

The onset of the COVID-19 pandemic has highlighted the necessity for experts from diverse disciplines to mitigate the most dangerous calamity facing humanity this century collaboratively. Researchers attempt to combine exponential advances in technology and scientific insight, resulting in an unprecedented speed of discovery in vaccine research and development. Since its establishment, MedInsights have been working with a core team of scientists from multiple disciplines to make transformative efforts through the willingness to share ideas, tackle challenges, and develop tools/ models. Headquartered in Paris, France, the company has employees working from the U.S, India, and Europe, focusing on maintaining strong communication channels as a critical part of its business processes. Its global multidisciplinary team works to understand the challenges and needs of clients to tailor a solution that meets their needs. In addition, MedInsights incorporates its multidisciplinary and multicultural philosophy into research training of its employees to contribute to the company objectives and foster personal development.
  • Our end-to-end analytics services aim to provide an edge to customers and enable them to understand their performance while at the same time maintaining the rigorous standards of scientific protocols


“Over the years, drug database repurposing has become one of the primary targets of pharma companies to fight against diseases using innovative data-driven approaches,” elucidates Manish. MedInsights has collaborated with a global key player in the pharma space to design, develop, and implement a Rare Disease database for their internal asset screening and enhance biomedical understanding. Its experts have joined the venture to evaluate the database’s strengths and weaknesses and propose improvements by providing strategic insights on pre-clinical research. The database, which spreads across a broad spectrum of modalities encompassing real-world data and evidence, can be used to predict outcomes of search with high confidence scores. The company uses these predictions to correlate with data from clinical research, which are either launched or experimental/in development. Currently, MedInsights is working on its in-house omics platform, which will go live this year. As the company aims to deploy the platform globally, it plans to develop support systems in different languages worldwide in the near future.

Website: MedInsights.fr
Contact: sophie@medinsights.fr